22nd Century Group, Inc. Files Investigational New Drug Application and Fast Track Request for X-22; Phase II-B Clinical Trial to Commence Immediately Upon FDA Clearance  
6/22/2011 9:08:27 AM

WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction, announced today that 22nd Century Limited, LLC submitted an Investigational New Drug Application (IND) to the U.S. Food & Drug Administration (FDA) for X-22, a prescription smoking cessation aid in development.